Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Ziopharm Oncology Promotes Dr. David Mauney to President
BOSTON , Dec. 13, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) today announced that David Mauney , M.D., has been promoted to President effective immediately. Dr. Mauney, who joined Ziopharm in 2017 as Executive Vice President and Chief Business Officer, will continue to report
View HTML
Toggle Summary Ziopharm Oncology Provides Controlled IL-12 Update with Positive Data from Phase 1 Trial Presented at Annual Meeting of the Society for Neuro-Oncology
Ad-RTS-hIL-12 plus 20mg veledimex (Controlled IL-12) determined to be preferred dosing with low-dose steroids to treat adult patients with recurrent glioblastoma Median overall survival for Ad-RTS-hIL-12 plus veledimex in patients receiving low-dose steroids is 17.8 months Controlled IL-12
View HTML
Toggle Summary Ziopharm Oncology to Host Conference Call Today at 8 a.m.
BOSTON , Nov. 12, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today will host a webcast and conference call today, Nov. 12 , at 8 a.m. ET . On the call, management will discuss recent corporate developments and the new collaboration with Regeneron Pharmaceuticals .
View HTML
Toggle Summary Ziopharm Oncology Announces Immuno-oncology Clinical Supply Agreement with Regeneron to Evaluate Combination Therapy for Patients with Brain Cancer
BOSTON , Nov. 12, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. , (Nasdaq:ZIOP) today announced a clinical supply agreement with Regeneron Pharmaceuticals, Inc. to evaluate Ziopharm’s Ad-RTS-hIL-12 plus veledimex in combination with Regeneron’s PD-1 antibody Libtayo ® (cemiplimab-rwlc) to treat
View HTML
Toggle Summary Ziopharm Oncology Announces $50 Million Private Placement
BOSTON , Nov. 12, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that it has entered into definitive securities purchase agreements for the sale of its common stock and warrants to purchase common stock in a private placement that is expected to result in gross
View HTML
Toggle Summary Ziopharm Oncology Third Quarter 2018 Financial Results Conference Call Rescheduled to Nov. 12
BOSTON , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP), today announced that it has rescheduled its quarterly conference call to Monday, Nov. 12 , at 8 a.m. ET to provide a corporate update and discuss financial results for the third quarter ended Sept.
View HTML
Toggle Summary Ziopharm Oncology to Present at the Stifel 2018 Healthcare Conference on Nov. 14
BOSTON , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper , M.D., Ph.D., Chief Executive Officer, will present at the Stifel 2018 Healthcare Conference in New York on Wednesday, Nov. 14 , at 1:15 p.m. ET .
View HTML
Toggle Summary Ziopharm Oncology to Present Update on Controlled IL-12 Brain Cancer Trial at Annual Meeting of the Society for Neuro-Oncology on Nov. 16
BOSTON , Nov. 05, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP), a biotechnology company focused on development of next generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer, today announced it will update data from its Phase 1 trial of
View HTML
Toggle Summary Ziopharm Oncology to Announce Third Quarter 2018 Financial Results, Host Conference Call Nov. 8
BOSTON , Oct. 31, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP), today announced that management will host a conference call and webcast slide presentation on Thursday, Nov. 8 , at 4:30 p.m. ET to provide a corporate update and discuss financial results for the third quarter ended
View HTML
Toggle Summary Ziopharm Oncology Announces Changes to Board of Directors and Management Team
-- CEO Laurence Cooper Appointed to Board of Directors  -- Francois Lebel to Depart Company BOSTON , Oct. 16, 2018 (GLOBE NEWSWIRE) --   Ziopharm Oncology , Inc. (Nasdaq:ZIOP), a biotechnology company focused on development of next generation immunotherapies utilizing gene- and cell-based therapies
View HTML